- 7
- 0
- 约1.19万字
- 约 7页
- 2017-05-30 发布于河南
- 举报
Sigma公司案例分析
Contents
Part 1
History and Major Activities 厖厖厖厖厖厖厖厖
Part 1 2
Part 2
Industry Characteristics
Rivalry Among Existing Firms厖厖厖厖厖厖厖3t 2
I
Threat of New Entrants厖厖厖厖厖厖厖厖?of New E3
Threat of Substitute Products 厖厖厖厖厖厖厖4f Subst
Bargaining Power of Buyers厖厖厖厖厖厖厖?ning Po4
Bargaining Power of Suppliers厖厖厖厖厖厖厖aining 5
Part 3
Competitive Strategy厖厖厖厖厖厖厖厖厖厖6
Competit
Reference 厖厖厖厖厖厖厖厖厖厖厖厖Competitve S7
Part 1 History and Major Activities
Sigma is a large company in the pharmaceutical industry and it has a long history. In 1912, two Melbourne pharmacists established it. After a prolonged endeavour, now Sigma plays an important role in this industry.
Sigma began its manufacturing activities in 1942. After fifty-four years, it acquired QDL. And in the next year, Sigma Company Ltd was listed on the Exempt Stock Exchange. Guardian pharmacy group and Amcal pharmacy group were acquired successfully in the following year. In 1999, Smith Kline Beechams Dandenong manufacturing facility was acquired. And in the same year, Sigma incorporated Arrow Pharmaceuticals, which was listed on the ASX in 2002. In 2003, Sigma Company acquired Herron Pharmaceuticals and Chemists Own. And in 2005, Sigma Company Ltd and Arrow Pharmaceuticals Ltd merged and are renamed Sigma Pharmaceuticals Ltd. In 2008, Sigma Pharmaceuticals acquires Orphan Australia. Recently, Sigma divested its Pharmaceutical Division to Aspen Pharmacare Holdings.
Now, Sigma engaged in the manufacturing, development and distribution of own branded and contract OTC (over the counter), prescription and generic pharmaceutical products for the Australian and overseas markets.. Sigma is also the owner of some of Australias best known pharmacy brands in Amcal, Guardian and Amcal Max.
Sigma Healthcare Division was created to align Sigma wholesale and retail services to provide even greater value to primary customer, Community Pharmacists. The Sigma Healthcare Division provides all pharmacist customers with an extensive range of
您可能关注的文档
- ICH E11——CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION.pdf
- 雅施达幻灯片-(kh).ppt
- (EC) No 1830_2003 关于转基因生物体的可溯性和标签及由转基因生物体生产的食品和饲料产品的可溯性.pdf
- 美国及欧盟审批生物仿制药制度对我国的启示--龚兆龙.pdf
- 2.3.1定性反应和测试(硫酸盐的鉴别反应)BP2015翻译.docx
- 对眼用制剂中抑菌剂质量控制的思考.doc
- 132对眼用制剂中抑菌剂质量控制的思考.docx
- 090226新型辅料安全性.ppt
- 医疗分子筛制氧焦点问题探讨.doc
- 欧州药典中两个植物来源药品的质量标准简介.docx
- 小区绿化施工协议书.docx
- 墙面施工协议书.docx
- 1 古诗二首(课件)--2025-2026学年统编版语文二年级下册.pptx
- (2026春新版)部编版八年级道德与法治下册《3.1《公民基本权利》PPT课件.pptx
- (2026春新版)部编版八年级道德与法治下册《4.3《依法履行义务》PPT课件.pptx
- (2026春新版)部编版八年级道德与法治下册《6.2《按劳分配为主体、多种分配方式并存》PPT课件.pptx
- (2026春新版)部编版八年级道德与法治下册《6.1《公有制为主体、多种所有制经济共同发展》PPT课件.pptx
- 初三教学管理交流发言稿.docx
- 小学生课外阅读总结.docx
- 餐饮门店夜经济运营的社会责任报告(夜间贡献)撰写流程试题库及答案.doc
原创力文档

文档评论(0)